Clozapine toxicity in smoking cessation and with ciprofloxacin.
Brownlowe
Katherine
K
Sola
Christopher
C
D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D003024:Clozapine / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D019388:Cytochrome P-450 CYP1A2 / Q000096:biosynthesis; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D006801:Humans; D008658:Inactivation, Metabolic; D008297:Male; D008875:Middle Aged; D009205:Myocarditis / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D012307:Risk Factors; D016540:Smoking Cessation; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000175:diagnosis* / Q000523:psychology; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy*
D014150:Antipsychotic Agents; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D065692:Cytochrome P-450 CYP3A Inhibitors; D002939:Ciprofloxacin; D019388:Cytochrome P-450 CYP1A2; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D003024:Clozapine